Serum untargeted metabolomic changes in response to diet intervention in dogs with preclinical myxomatous mitral valve disease
Authors:
Open Access
- 18 June 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6) , e0234404
Abstract
Myocardial energy deprivation plays a causal role in the development of heart failure. A cardiac protection blend (CPB) of nutrients including medium chain triglycerides, fish oil and other key nutrients was developed to slow the progression of canine myxomatous mitral valve disease (MMVD). A six-month dietary intervention demonstrated efficacy of CPB in slowing MMVD progression. Untargeted metabolomic analysis of serum from these dogs identified 102 differential metabolites (adjusted P < 0.05). The ratios of omega-6 to omega-3 fatty acid (FA) changed from 2.41 and 1.46 in control and CPB groups at baseline to 4.30 and 0.46 at 6 months respectively. A 2.7-fold increase of α-aminobutyrate, a myocardial modulator of glutathione homeostasis, was found in CPB dogs compared to 1.3-fold increase in control dogs. Arginine and citrulline, precursors of nitric oxide biosynthesis, were both increased 2-fold; caprate, a medium chain FA, was increased 3-fold; and deoxycarnitine, precursor of carnitine biosynthesis, was increased 2.5-fold in CPB dogs. Margarate and methylpalmitate decreased in response to CPB, a potential benefit in MMVD dogs as positive correlations were found between changes in both these FAs and left atrial diameter (r = 0.69, r = 0.87 respectively, adjusted P < 0.05). Sphingomyelins with very long chain saturated FAs associated with decreased risk of heart failure in humans were increased in MMVD dogs fed the CPB diet. Our data supports the hypothesis that CPB improves FA utilization and energetics, reduces oxidative stress and inflammation in MMVD dogs. More studies are needed to understand the roles of specific metabolites in MMVD.Keywords
This publication has 69 references indexed in Scilit:
- Cardiac Metabolism in Heart FailureCirculation Research, 2013
- Metabolomic Profiling for the Identification of Novel Biomarkers and Mechanisms Related to Common Cardiovascular DiseasesCirculation, 2012
- Plasma Phospholipid Fatty Acid Concentration and Incident Coronary Heart Disease in Men and Women: The EPIC-Norfolk Prospective StudyPLOS Medicine, 2012
- Metabolic profiles predict adverse events after coronary artery bypass graftingThe Journal of Thoracic and Cardiovascular Surgery, 2012
- Modulating fatty acid oxidation in heart failureCardiovascular Research, 2011
- Beneficial effects of omega‐3 fatty acids in cardiovascular diseaseJournal of Small Animal Practice, 2010
- Plasma Acylcarnitine Profiles Suggest Incomplete Long-Chain Fatty Acid β-Oxidation and Altered Tricarboxylic Acid Cycle Activity in Type 2 Diabetic African-American WomenThe Journal of Nutrition, 2009
- The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic DiseasesExperimental Biology and Medicine, 2008
- Medium-chain Fatty Acids as Metabolic Therapy in Cardiac DiseaseCardiovascular Drugs and Therapy, 2008
- The Failing Heart — An Engine Out of FuelNew England Journal of Medicine, 2007